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Disorders of Golgi homeostasis form an emerging group of genetic defects. The highly heterogeneous clinical spectrum is not explained by
our current understanding of the underlying cell-biological processes in the Golgi. Therefore, uncovering genetic defects and annotating
gene function are challenging. Exome sequencing in a familywith three siblings affectedby abnormalGolgi glycosylation revealed ahomo-
zygous missense mutation, c.92T>C (p.Leu31Ser), in coiled-coil domain containing 115 (CCDC115), the function of which is unknown.
The samemutationwas identified in three unrelated families, and in one family it was compoundheterozygous in combinationwith a het-
erozygous deletion of CCDC115. An additional homozygous missense mutation, c.31G>T (p.Asp11Tyr), was found in a family with two
affectedsiblings.All individualsdisplayeda storage-disease-likephenotype involvinghepatosplenomegaly,whichregressedwithage,highly
elevated bone-derived alkaline phosphatase, elevated aminotransferases, and elevated cholesterol, in combination with abnormal copper
metabolismandneurological symptoms.Two individuals diedof liver failure, andone individualwas successfully treatedby liver transplan-
tation. AbnormalN- andmucin typeO-glycosylationwas foundon serumproteins, and reducedmetabolic labeling of sialic acidswas found
in fibroblasts, whichwas restored after complementationwithwild-typeCCDC115. PSI-BLAST homology detection revealed reciprocal ho-
mologywithVma22p, the yeast V-ATPase assembly factor located in the endoplasmic reticulum (ER).HumanCCDC115mainly localized to
the ERGIC and to COPI vesicles, but not to the ER. These data, in combination with the phenotypic spectrum, which is distinct from that
associatedwithdefects inV-ATPase core subunits, suggest amoregeneral role forCCDC115 inGolgi trafficking.Our study revealsCCDC115
deficiency as a disorder of Golgi homeostasis that can be readily identified via screening for abnormal glycosylation in plasma.Introduction
Congenital disorders of glycosylation (CDGs) are a hetero-
geneous group of monogenic diseases affecting the glyco-
sylation of proteins and lipids. Approximately 100 CDGs
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glycosylation can be divided into type 1 CDGs, affecting
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the Golgi apparatus and the heterogeneous phenotype of
individuals with CDGs, making phenotypic clustering
difficult. Type 2 CDGs can be further grouped on the basis
of disease mechanism. Mutations in genes encoding for
proteins directly involved in Golgi glycosylation (e.g.,
SLC35A1 [MIM: 605634], B4GALT1 [MIM: 137060], and
MGAT2 [MIM: 602616]) were the first to be discovered.2–4
Another group of type 2 CDGs are caused by disturbances
in Golgi homeostasis. This group encompasses several
conserved oligomeric Golgi (COG)-CDGs, TMEM165-
CDG (MIM: 614726) and ATP6V0A2-CDG (MIM:
611716). The COG complex is involved in retrograde Golgi
transport, and mutations lead to abnormal distribution of
proteins involved in the glycosylation machinery, such as
glycosyltransferases.5 TMEM165 mutations were recently
described in individuals with skeletal symptoms and
linked with deficient Ca2þ and pH homeostasis.6,7
ATP6V0A2 mutations were described in autosomal-reces-
sive cutis laxa type 2 (ARCL2 [MIM: 219200]).8 ATP6V0A2
encodes a subunit of the vacuolar Hþ ATPase (V-ATPase),
which is primarily responsible for acidification of organ-
elles within the secretory pathway and endolysosomal sys-
tem.9 Fibroblasts from ARCL2-affected individuals show
delayed retrograde Golgi transport, in accordance with
the versatile role of the V-ATPase and its involvement in
multiple cellular processes.10,11
Traditionally, diagnostics for protein N-glycosylation de-
fects is performed with isoelectric focusing (IEF) of serum
transferrin (Tf). This method is used to distinguish be-
tween type 1 and type 2 CDGs.12 Additionally, IEF of
serum apolipoprotein C-III (ApoC-III) can detect abnormal
mucin-type O-glycosylation.13 Recently, we described the
use of a high resolution nanochip-C8 QTOF mass spec-
trometry method for annotation of glycan structures on
intact serum Tf.14 This method provides additional glycan
information, such as loss of galactose.
Here,we report the identificationofpathogenicmutations
in coiled-coil domain containing 115 (CCDC115 [GenBank:
NM_032357.3], UCSC Genome Browser [GRCh37/hg19],
chr2:131,095,506–131,099,956) in five unrelated families
with abnormal N- and mucin type O-glycosylation, sugges-
tive of a Golgi homeostasis defect.Material and Methods
Participating Individuals
Blood and, if obtained, fibroblasts of participating individuals
were sent to the RadboudUniversityMedical Center, Translational
Metabolic Laboratory, for CDG diagnostics, based on clinical sus-
picion for an inborn error of metabolism. All participating affected
individuals or their legal representatives gave informed consent
for exome sequencing. Tissue and samples were obtained in accor-
dance with the Declaration of Helsinki.
Exome Sequencing and Interpretation
Next-generation sequencing and analysis were performed as
described earlier.15 The SureSelect Human All Exon 50 Mb KitThe Americ(v.4, Agilent) was used for exome enrichment, covering ~21,000
genes. The exome library was sequenced on a 5500xl SOLiD
sequencer (Life Technologies). Color space reads were iteratively
mapped to the hg19 reference genome with the SOLiD LifeScope
software v.2.1. We used our in-house annotation pipeline for
annotation of called variants and indels.16
Variants were excluded based on a frequency of>0.2% in our in-
house database of >1,300 exomes. Also, synonymous variants,
deep intronic variants, and variants in UTRs were excluded. Qual-
ity criteria were applied and included variants called more than
five times and with variation of more than 20% for heterozygous
variants and 80% for homozygous variants.Bioinformatics
Amino acid sequences of humanCCDC115 andhomologs of other
species were aligned and visualized with Jalview v.2.8 (see Web
Resources). The following accession numbers were used for the
alignment in Figure 1B: GenBank: NP_115733.2 (H. sapiens);
GenBank: NP_081435.1 (M. musculus); GenBank: NP_001013313.
1 (D. rerio); GenBank: NP_649550.1 (D. melanogaster); GenBank:
NP_011927.1 (S. cerevisiae S288c); GenBank: NP_173500.1
(A. thaliana).Mutation Analyses
In silico analysis was done with Alamut v.2.4.6 (Interactive Bio-
software) and the effects of mutations were predicted with SIFT,
PolyPhen, and MutationTaster (see Web Resources). The Exome
Aggregation Consortium (ExAC) database (see Web Resources)
was used for allele frequency.
Primers (Biolegio and Sigma-Aldrich) flanked with universal
M13 tags were constructed with the help of the UCSC Genome
Browser, Primer3, and SNPCheck3 (see Web Resources).17,18 For a
list of primers used, see Table S1. Sanger sequencing was per-
formed on DNA isolated from peripheral blood or cultured fibro-
blasts, according to standard protocols. DNA was amplified with
a T100 ThermoCycler (Bio-Rad). An ABI 3730 DNA Analyzer
(Life Technologies) was used for sequencing. Data analysis was
done with Sequencher 4.8 (Gene Codes).
Multiplex ligation-dependent probe amplification (MLPA) was
performed as described previously.19 In short, combinations of
two adjacently annealing oligonucleotide probes were hybridized
and ligated. After ligation, the common ends of the probes served
as a template for PCR amplification with one primer pair, and due
to the fluorescent labeling of the primer, the resulting products
could be separated according to size via capillary electrophoresis
on an ABI3130 Genetic Analyzer (Applied Biosystems). Fragment
datawere analyzed inGeneScan (AppliedBiosystems). Peakheights
of samples from affected individuals were compared with those
from control individual probes, and ratios were calculated for all
fragments (originating from CCDC115, PTPN18, and SMPD4
exons)via anExcel spreadsheet. Thresholds fordeletions anddupli-
cations were set at 0.75 and 1.25 respectively, and all samples were
tested at least twice. All reagents for the MLPA reaction and subse-
quent PCR amplification were purchased from MRC-Holland,
with exception of the CCDC115, PTPN18, SMPD4, and control
primers (Biolegio). Primer sequences are described in Table S1.Cell Culture
Skin fibroblasts from participants and healthy control individuals
were cultured at 37.0C under 5.0% CO2 in culture medium
E199, supplemented with 10% fetal calf serum, and 1%an Journal of Human Genetics 98, 310–321, February 4, 2016 311
Figure 1. Pedigrees and Overview of the Structure, Variants, and Conservation of CCDC115
(A) Pedigrees and chromatograms of families F1 to F5 are shown. Partial chromatograms show autosomal-recessive segregation for all
families. For family F3, DNA for parents and the healthy sibling was not available. For affected individual F4-II1, DNA was unavailable.
The asterisk indicates the respective nucleotide change.
(B) Schematic representationof the intron-exon structure andhomologyofCCDC115. The red lines indicate the positions of themissense
mutations and substitutions within the families. The green regions indicate the two predicted coiled-coil domains (CC1 and CC2).penicillin/streptomycin. All cultures were tested for mycoplasma
infection prior to cultivation.
Cloning Studies
CCDC115 Wild-Type Sequence in pLIB-GSKBrd for Transfection in Skin-
Derived Fibroblasts
A retroviral pLIB construct was purchased from Clontech, and a
PGK-Blasticidin resistant cassette was introduced to create a
pLIB-PGKBsr vector. Human CCDC115 was then cloned into this
vector. Skin fibroblasts from individual F1-II4 were transfected
with either pLIB2-pgkBsr construct (empty vector) or pLIB2-
CCDC115-PGKBsr construct.
pcDNA3.1-CCDC115-V5-His for Transfection in HeLa cells
CCDC115 cDNA was obtained from healthy control fibroblasts
with the Transcriptor First Strand cDNA Synthesis Kit (Roche) and
primers spanning the whole cDNA (see Table S1 for primer se-
quences). cDNA was sequenced and cloned into the mammalian
expressionvectorpcDNA3.1_V5_HisTOPO-TA (LifeTechnologies).
The construct was checked via Sanger sequencing and transformed
in competentE. coli. DNAwas extractedwith theBirnboimmethod
and checked for correct placement of the CCDC115 strand.20
Plasmid purificationwas donewith the PlasmidMidi Kit (QIAGEN)
according to the manual. Transfection was done with FuGENE HD
Transfection Reagent (Promega) on coverslips coated with poly-L-
Lysine (Sigma) and incubated overnight in DMEM (GIBCO) with
30%–50% confluency for immunofluorescence studies.312 The American Journal of Human Genetics 98, 310–321, FebruaryImmunofluorescence
48hr after transfectionofHeLa cellswithpcDNA3.1-CCDC115-V5-
His, cells were fixedwith 3.7% paraformaldehyde (PFA) for 12min,
washed three times in PBS, and permeabilized with 0.1% Triton in
3% BSA/13 PBS at 4C for 10 min. After washing in PBS, cells were
blocked for 30 min with 3% BSA/13 PBS solution. Primary anti-
bodies were diluted in 3% BSA/13 PBS. Cells were incubated with
primary antibody in a wet environment for 1 hr at room tempera-
ture (RT) and, after washingwith PBS, incubated for 1.5 hrwith sec-
ondary antibodies in 3% BSA/13 PBS. After washing the cells three
times with PBS and once with distilled water, they were mounted
ona slidewithProlongGold antifadewithDAPI (Life Technologies)
and left to dry at RT for at least 24 hr. Under identical settings, the
cellswere visualizedwith a confocal Leica SP8 (LeicaMicrosystems)
with603water immersionand1.2NAobjective. Pictureprocessing
was donewith ImageJ software v.1.46 (seeWeb Resources). Primary
antibodies used are as follows: anti-V5-Tag (1:200, Life Technolo-
gies, #R960-25), anti-beta COP (1:1,000, Abcam, #ab2899), anti-
SEC31A (1:500, Sigma-Aldrich, #HPA005457), anti-Giantin
(1:1,000, BioLegend, #prb-114c), anti-ERGIC53/p58 (1:200,
Sigma-Aldrich, #E1031), anti-PDI (1:500, Abcam, #ab3672), anti-
Calnexin (1:200, StressMarqBiosciences, #SPC-108). Secondary an-
tibodies are as follows: Alexa Fluor 488-conjugated goat anti-mouse
IgG (HþL) (1:1,000, Life Technologies, #A-11029) and Alexa Fluor
568-conjugated goat anti-rabbit IgG (HþL) (1:1,000, Life Technolo-
gies, #A-11011).4, 2016
IEF of Tf and ApoC-III
Tf IEF was performed as previously described.21 In short, 10 ml
serum or plasma sample was added to a solution containing iron
and NaHCO3, electrophorized on a 5–7 pH gradient gel, and incu-
bated with 60 ml polyclonal rabbit anti-Tf antibody (Dako,
#A0061). Quantification of the gel was done with Image Quant
software (TotalLab). Neuraminidase treatment was performed
when a Tf polymorphism was suspected as described earlier.21
ApoC-III IEF was performed as described, but with small modifi-
cations.13 In short, 2 ml of serum/plasma was 153 diluted with sa-
line solution. Before electrophoresis, the gel was rehydrated in a
solution containing 8 M urea. After blotting on a nitrocellulose
membrane filter, the blot was washed and blocked before incuba-
tion with anti-ApoC-III (1:2,000, Rockland, #600-101-114). After
incubation with the secondary anti-goat-HRP antibody (1:5,000,
Thermo Scientific, #31402) and ECL reagent (Pierce), the blot
was visualized on a LAS3000 imaging system (Fujifilm). Blot quan-
tification was done with Image Quant software.MALDI-LTQ Mass Spectrometry
Mass spectrometry of total plasma N-glycans was performed as
described earlier.22 To summarize, glycans from 10 ml plasma
were cleaved with PNGaseF (NE Biolabs) and incubated overnight.
After purification on graphitized carbon SPE columns, the glycans
were permethylated, purified again, and eluted in 50 ml of 75% v/v
aqueous acetonitrile. The glycans were dried and resuspended in a
methanol/sodium acetate mixture for spotting. Measurements
were done on a vMALDI-LTQ (Thermo Scientific).Nanochip-C8 QTOF Mass Spectrometry of Intact Tf
For high-resolution mass spectrometry of the intact Tf protein,
10 ml of serum sample was incubated with anti-Tf beads before in-
jection, and the eluate was analyzed on amicrofluidic nanoLC-C8-
chip 6540 QTOF instrument (Agilent Technologies).14 Agilent
Mass Hunter Qualitative Analysis Software B.04.00 was used for
data analysis. For deconvolution of the charge distribution raw
data, Agilent BioConfirm Software was used.Metabolic Labeling with Alkyne-Tagged Modified
Sugar
Metabolic labeling was performed as described before.23 Primary
skin fibroblasts were maintained in DMEM supplemented with
10% fetal bovine serum (Lonza), at 37C under 5% CO2 atmo-
sphere. Fibroblasts were grown overnight on glass coverslips
(12 mm diameter). Medium was then changed with pre-warmed
medium containing 500 mM of alkynyl-modified sugar (ManNAl,
provided by Dr. Y. Geurardel and Prof. C. Biot). Labeling lasted
8 hr or 6 hr. The labeling was stopped by fixing the cells with 4%
PFA. Cells were then permeabilized in 0.5% Triton X-100 for
10 min. After washes, cells were incubated in the click chemistry
buffer containing CuSO4, 5H2O-BTTAA-ascorbate-potassium
phosphate, and azide-fluor 545 (Sigma, #760757). The pool of fluo-
rescent glycoconjugates was visualized through an inverted Leica
TCS-SP5 confocal microscope. Pictures were taken with the Leica
Application Suite Advanced Fluorescence (LAS AF) software (Leica
Microsystems). For comparison purposes, each picture was taken
under the same settings. TISGolgi was used to automatically detect
theGolgi area andmeasure theGolgi fluorescence. This homemade
ImageJ plugin was developed by TISBio (seeWeb Resources). Three
different fields of two independent experiments were examined.The AmericResults
Clinical Phenotype
All affected individuals (see pedigrees in Figure 1A and
overview in Table 1) had a similar phenotype with
storage-disease-like symptoms at a younger age. These
included hepatosplenomegaly, hypotonia, elevated serum
aminotransferases (ATs, composed of aspartate and alanine
aminotransferases [AST, ALT]), and elevated serum alkaline
phosphatase (ALP). Additional symptoms included psy-
chomotor disability (PMD), mild hypercholesterolemia,
and low serum ceruloplasmin.
Siblings F1-II1 (female, born in 2000) and F1-II2 (male,
born in 2004) from family F1 were from Turkish ancestry
and have been described previously.24 Their parents are first
cousins. During our studies, a younger affected sister was
born (individual F1-II4, female, born in 2012). Overall, their
symptoms were dominated by PMD, hypotonia, and hepa-
tosplenomegaly with elevated AT and ALP. Metabolic
screening revealed a type 2 CDG profile. Individual F1-II1
was first seen at the age of nine years. Her neonatal period
was unremarkable. At examination there was a generalized
hypotonia andPMD.She showedmilddysmorphic features.
Over the years her AT and ALP fluctuated but were always
elevated (AST 130–158 U/l [normal range, 0–50 U/l], ALT
85–101 U/l [normal range, 0–50 U/l], and ALP 1,016
–1,193 U/l [normal range, < 360 U/l]). Isotype analysis
showed that ALPwasmostly bone derived, as seen in defects
of glycosylphosphatidylinositol (GPI)-anchor biosynthesis.
However, surface expression of GPI-anchored proteins
CD59 and CD55 in EBV-transformed lymphoblasts did not
confirm a GPI-anchor defect (data not shown). Additional
biochemical analysis showed low serum ceruloplasmin
(4 mg/dl [normal range, 15–60 mg/dl]), decreased coagula-
tion factors, and elevated creatine kinase. Total cholesterol
and low-density lipoprotein (LDL-C) were normal. Her
brother, F1-II2, was also seen in 2009 at the age of five years.
He shared the same phenotype as his sister but had addi-
tional dysmorphic features (long face, ptosis, blue sclera,
and down-slanting palpebral fissures). In addition to gener-
alized hypotonia, muscle atrophy was present. Biochemi-
cally, elevated AT and ALP (AST 96–436 U/l, ALT 140–
995 U/l, and ALP 1,070–1,577 U/l), low ceruloplasmin
(4 mg/dl), hypercholesterolemia (289 mg/dl [normal range,
120–200 mg/dl]), and abnormal coagulation factors were
seen over time. Individual F1-II4 was last seen in 2014 at
the age of two years. The most prominent finding was
PMD. Hypotonia was not present. Hepatic evaluation
showed elevated AST (1,089 U/l), ALT (591 U/l), ALP
(1,251 U/l), and profound hepatosplenomegaly, similar to
lysosomal storage disorders in the first years of life. Organ
size normalized with increasing age.
Individual F2-II1 (male, born in 2008) from family F2
was the only child of unrelated Italian parents. As a
neonate, he suffered from prolonged neonatal jaundice
and elevated AST, ALT, and hepatosplenomegaly. Low
serum ceruloplasmin and hypercholesterolemia werean Journal of Human Genetics 98, 310–321, February 4, 2016 313
Table 1. Overview of the Genetic and Clinical Features of the CCDC115-Deficient Families
Family
Individual
(y.o.b.) Zygosity
Allele
Frequency
(ExAC)
gDNA Change
(chr2) cDNA Change
Protein
Change
Abnormal Glycosylation
Elevated
ATs
Elevated
ALP
Elevated
Cholesterol
and LDL-C
Cerulo
plasmin
Hepatic
Phenotype
Neurological
PhenotypeN O
F1 F1-II1 (2000),
F1-II2 (2004),
F1-II4 (2012)
homozygous 8.253e-06 g.131099607A>G c.[92T>C];
[92T>C]
p.[Leu31Ser];
[Leu31Ser]
þ þ þ þþ þ low hepatomegaly hypotonia,
PMD
F2 F2-II1 (2008) homozygous 8.253e-06 g.131099607A>G c.[92T>C];
[92T>C]
p.[Leu31Ser];
[Leu31Ser]
þ þ þ þþ þ low hepatomegaly,
copper
accumulation
PMD
F3 F3-II2 (1989) homozygous 8.253e-06 g.131099607A>G c.[92T>C];
[92T>C]
p.[Leu31Ser];
[Leu31Ser]
þ n.d. þ þþ þ low fibrosis, steatosis,
necrotic lesions
hypotonia,
PMD,
seizures
F4a F4-II1 (2002),
F4-II2 (2003)
homozygous 0 g.131099668C>A c.[31G>T];
[31G>T]
p.[Asp11Tyr];
[Asp11Tyr]
þ þ þ þþ þ n.d. liver failureb 
F5c F5-II1 (2014) compound
heterozygous
8.253e-06 /
NA
g.131099607A>G /
g.(130939272_
131096872)_
(131116671_?)del
c.[92T>C];
[(?_-258)_
(*1245_?) del]
p.[Leu31Ser];
[p.0?]
þ þ þ þþ þ n.d. hepatomegaly,
cirrhosis,
liver failure
hypotonia
Abbrevations are as follows: y.o.b., year of birth; N, N-glycosylation measured by IEF of serum Tf; O, O-glycosylation measured by IEF of serum ApoC-III; LDL-C, low-density lipoprotein; ATs, serum aminotransferases; ALP,
serum alkaline phosphatase; PMD, psychomotor disability; n.d., not determined; NA, not applicable.
aSibling F4-II1 died at the age of 9 years as a result of liver failure after repeated liver transplantation.
bBoth siblings underwent liver transplantation.
cIndividual F5-II1 died of liver failure at the age of 7 months.
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found. On suspicion of Wilson disease (WD [MIM:
277900]), zinc treatment was started but proved unsuccess-
ful. Genetic screening for WD failed to detect mutations in
ATP7B (MIM: 606882). At the age of two years, examina-
tions showed mild PMD and mild dysmorphic features.
Biochemical analysis revealed elevated AT and ALP (AST
422 U/l, ALT 588 U/l, ALP 976 U/l), low ceruloplasmin
(3.3 mg/dl), high cholesterol (381 mg/dl), and high
LDL-C (332 mg/dl [normal range, 50–130 mg/dl]). Meta-
bolic diagnostics showed a type 2 CDG pattern. A liver bi-
opsy at the age of three years showed an increased hepatic
copper concentration of 125 mg/g dry weight (normal
range, <40 mg/g dry weight; WD, >250 mg/g dry weight).
Individual F3-II2 (female, born in 1989) from family F3
was the second child of unrelated French parents. She
had an uncomplicated birth but developed neonatal jaun-
dice, which was treated successfully by phototherapy. This
was accompanied by elevated AT and ALP. She was hospi-
talized at the age of one year due to persistentmoderate hy-
potonia. Biochemically, she had elevated AST (1,780 U/l),
ALT (390 U/l), and ALP (950 U/l, with increased bone frac-
tion). Steatosis, fibrosis, and necrotic lesions were seen on
liver biopsy. During childhood, she developed PMD with
hypotonia and seizures. Biochemically, elevated AT and
ALP persisted. At a later age, she developed hypercholester-
olemia. CDG screening showed a type 2 pattern. During
her last visit at the age of twenty-five years, she still suf-
fered from PMD, as well as additional behavioral problems
such as aggressiveness, agitation, and psychotic behavior,
for which she is being treated with risperidone. Her sei-
zures persisted despite treatment with lamotrigine. Serum
AT and ALP remain elevated (AST 82 U/l, ALT 76 U/l, ALP
180 U/l) and ceruloplasmin low (10 mg/dl).
Individuals F4-II1 (male, born in 2002, died in 2011)
and F4-II2 (female, born in 2003) are brother and sister
and were born to consanguineous Turkish parents. As a
neonate, individual F4-II1 showed neonatal jaundice. Pro-
gressive cholestatic liver disease was diagnosed at an early
age.Due toprogressive liver failure, siblingF4-II1underwent
a liver transplantation at the age of three years and ten
months, and sibling F4-II2 at the age of eight years.Unfortu-
nately, the transplant of sibling F4-II1 was rejected twice,
and he died at the age of nine years. Both siblings showed
mild dysmorphic features and individual F4-II1 had a mild
PMD. They showed elevated AT and ALP during several
check-ups (F4-II1: AST 192–669 U/l, ALT 83–308 U/l, ALP
702 U/l; F4-II2: AST 98–422 U/l, ALT 98–178 U/l, ALP 710–
985 U/l). Ceruloplasmin was never measured. After liver
transplantation, individual F4-II2 is doing well. Among
other parameters, her ATandCDG profile have normalized.
Individual F5-II1 (female, born in 2014, died after seven
months) was the only child of non-consanguineous Portu-
guese parents. Jaundice was noticed since the first day of
life. At five months, jaundice persisted and she developed
hepatosplenomegaly, failure to thrive, redundant skin,
poor muscle volume, and generalized hypotonia. There
were no signs of PMD. Her parents refused a liver biopsy.The AmericIntermittent episodes of hypoglycemia and hyperammo-
nemia ensued. Subsequently, she developed progressive
cholestatic liver disease (bilirubin 41.3 mg/dl, 40% conju-
gated) and liver failure. Investigation showed increased
ATs (AST 207–972 U/l, ALT 48–153 U/l) and ALP (850–
1,031 U/l). Additional biochemical analysis revealed hy-
percholesterolemia (431 mg/dl) and elevated LDL-C
(314 mg/dl), abnormal coagulation factors (low FVII and
high FVIII, INR 0.79–3.0), and anemia (Hb 7 g/dl) with
acanthocytes and 7% reticulocytes. Interestingly, a bone
marrow biopsy showed dyserythropoiesis, some lipidic his-
tiocytes, and erythrophagocytosis. Later on, generalized
cell vacuolization and few erythroblasts with perinuclear
deposition of iron were seen. CDG screening revealed a
type 2 pattern. Liver transplantation was not attempted
due to rapid deterioration with multi-organ failure and en-
cephalopathy. She died at the age of seven months. Post-
mortem liver analysis revealed severe cholestatic hepatitis
with complete septal fibrosis and cirrhosis.
Mutational Analyses
To uncover the genetic defect, we performed exome
sequencing of individuals F1-II1 and F1-II2 from index fam-
ily F1. Eight possible candidates were identified on the basis
of having autosomal-recessive inheritance (Table S2).
Among these candidates was a homozygous missense
variant in CCDC115 (c.92T>C [p.Leu31Ser]) (Table 1).
We performed a profile-basedmethod, Position-Specific Iter-
ated (PSI)-BLAST,25 to identify possible homologs of the
candidate variants and identified Vma22p (GenBank:
NP_011927.1) as the yeast homolog of CCDC115
(GenBank: NP_115733.2) in the second iteration with
an E-value of 2e-14 and a reciprocal E-value of 3e-11.
Vma22p is a dedicated ER-localized assembly factor of the
V-ATPase.9,26,27 Importantly, Vma22p and CCDC115 were
found as each others’ best hits. This suggests that, apart
frombeinghomologs, they are likelyorthologswithoverlap-
ping functions in humans.28 Based on the link between the
V-ATPase and abnormal glycosylation, this variant was
considered our most likely candidate.7 This was further sup-
ported by homozygositymapping, indicating a small homo-
zygous region on chromosome 2, in which CCDC115 was
located (Figure S1). In silico analysis of the p.Leu31Ser substi-
tution with SIFT, PolyPhen-2, andMutationTaster predicted
pathogenicity (Table S3). The ExAC database showed a very
low allele frequency of 8.253e-06. Sanger sequencing
confirmed homozygosity for the affected individuals, het-
erozygosity for both parents, and homozygous wild-type
sequence for a healthy sibling, confirming complete segrega-
tion in the family (Figure 1A).Western blotting of fibroblasts
derived from individual F1-II4 demonstrated a protein level
similar to that of healthy control individuals (Figure S2).
For individuals F2-II1 and F5-II1, exome sequencing
revealed multiple genetic variants, among which was the
same c.92T>C homozygous missense variant (Table 1).
Sanger sequencing for individual F2-II1 confirmed homo-
zygosity and heterozygosity for the parents (Figure 1A).an Journal of Human Genetics 98, 310–321, February 4, 2016 315
Figure 2. CCDC115-Deficient Individuals
Have Abnormal Golgi Glycosylation
(A) IEF of serum Tf (left) and serum ApoC-
III (right). For individual F2-II1, HPLC was
used to assess Tf glycosylation status.
Reference ranges and quantifications are
shown in Tables S5 and S6.
(B) MALDI-LTQmass spectrometry profiles
of total serum N-glycans of a representa-
tive healthy control individual and of indi-
vidual F1-II1. An increase in hypoglycosy-
lated glycans with loss of sialic acid
(purple diamond) and galactose (yellow
dot) can be seen for individual F1-II1.
(C) For individual F1-II1 and his unaffected
mother, nanochip-C8 QTOF mass spectra
are shown for the intact Tf protein
(including two attached glycans) at
79,555 amu (peak 1). Any subsequent loss
of sialic acid and/or galactose can be calcu-
lated on the basis of mass difference with
the main peak. Individual F1-II1 shows a
reduction in sialic acid and galactose resi-
dues (peaks 2–8, see Table S7 for glycan
structures). m/z, mass-to-charge ratio;
amu, atomic mass units.For individual F5-II1, Sanger sequencing of parental DNA
revealed amaternal heterozygous missense mutation and a
paternal wild-type sequence (Figure 1A). We suspected a
paternal deletion as possible explanation, given that haplo-
type analysis excluded non-paternity. MLPA of DNA from
individual F5-II1 displayed a heterozygous deletion for all
exons ofCCDC115 andon the studied position in upstream
PTPN18 (Table S4).Wedidnot observe a deletion for the po-
sitionwe investigated within downstream SMPD4. Segrega-
tion analysis showed that the deletion originated from the
paternal allele. This complete deletion of CCDC115 is in
agreement with the severe phenotype of individual F5-II1.
Sanger sequencing of additional individuals with un-
solved Golgi glycosylation defects identified missense
mutations in CCDC115 in individuals from two unrelated
families: individual F3-II2 with the same homozygous
c.92T>C mutation and siblings F4-II1 and F4-II2 with a
homozygous missense mutation, c.31G>T, leading to a
p.Asp11Tyr substitution (Figure 1A and Table 1). The
p.Asp11Tyr substitution was also predicted to be patho-
genic by SIFT, PolyPhen-2, and MutationTaster (Table S3).
The allele frequency in the ExAC database was 0. In total,
we found two missense mutations and one deletion in
eight individuals from five families.316 The American Journal of Human Genetics 98, 310–321, February 4, 2016CCDC115 is located on the nega-
tive strand, contains five exons, and
encodes coiled-coil domain contain-
ing 115 with 180 amino acids and
two predicted coiled-coil domains
(Figure 1B). Both CCDC115 missense
mutations are located in the first
predicted coiled-coil domain and
affect highly conserved positions.CCDC115 is widespread among eukaryotes, including
Arabidopsis thaliana, indicating its origin at the root of
the eukaryotic tree.
Glycosylation Studies
Global defects in glycosylation can be detected by IEF of
serum Tf (N-glycosylation) and serum ApoC-III (mucin-
type O-glycosylation). Tf has two N-glycosylation sites,
and the most abundant fraction corresponds with four
sialic acids. ApoC-III has one mucin-type O-linked glycan
that canhost one or two sialic acids. An increase in fractions
associated with hyposialylated Tf or ApoC-III is indicative
of abnormal N- or O-glycosylation. All individuals showed
a similarly abnormal type 2 N-glycosylation profile of Tf
(see Figure 2A and Table S5 for quantifications). ApoC-III
IEF was abnormal for all tested individuals (see Figure 2A
and Table S6 for quantifications).
We performed MALDI-LTQ mass spectrometry of total
plasma N-glycans of individual F1-II1 and compared the
spectrum with that of a healthy control individual. Most
notably, the glycans with theoretical masses of 2,433 m/z
and 2,229 m/z were increased, indicating loss of either
one sialic acid (2,433 m/z) or one sialic acid plus one galac-
tose (2,229 m/z) (Figure 2B).
Figure 3. Metabolic Labeling of Sialic Acids Shows Decreased Glycosylation in CCDC115-Deficient Fibroblasts
(A and B) Metabolic labeling of fibroblasts with alkynyl-tagged sialic acid precursor ManNAl for 8 hr. Fibroblasts from three healthy con-
trols were used, and the experiment was performed twice. A reduced absolute Golgi fluorescence signal was observed for siblings F1-II1
and F1-II2. Scale bars indicate 75 mm.
(C and D) Fibroblasts of F1-II4, transfected with empty vector or wild-type CCDC115, were incubated withManNAl for 6 hr, followed by
fluorescent staining. The graphs indicate the absolute Golgi fluorescence intensity in a.u. Scale bars indicate 50 mm.
(E) Healthy control fibroblasts and fibroblasts from CCDC115-deficient individual F2-II1 were stained with anti-calnexin antibody. The
graph shows the percentage of cells with a dilated ER. Approximately 50 cells were counted, and the experiment was performed twice.
The graph shows the percentage of cells (mean5 SEM) with a dilated ER. Scale bars indicate 10 mm. N.D., not detectable.In accordance with total plasma N-glycan analysis, nano-
chip-C8 QTOF mass spectrometry of intact serum Tf
(79,555 amu, peak 1) showed accumulation of incomplete
glycans lacking sialic acid (79,265 amu, peak 2), galactose
(79,104 amu, peak 3), and additional minor isoforms lack-
ing sialic acid and/or galactose in individual F1-II1
(Figure 2C, peaks 4–8, see Table S7 for a list of all annotated
glycan structures). This pattern is compatible with an over-
all detrimental effect on Golgi glycosylation. Together with
abnormal O-glycosylation, these data are suggestive of a
Golgi homeostasis defect and a combined disorder of N-
glycosylation and mucin-type O-glycosylation.
Metabolic Labeling of Sialic Acids
We further assessed glycosylation efficiency in skin-derived
fibroblasts by metabolic labeling of sialic acids with alkyne-
tagged synthetic sugar analogs. These alkyne-tagged sialic
acids are incorporated into nascent glycoproteins by theThe Americcell allowing for specific detectionwith fluorescently labeled
azides.23 InCCDC115-deficient individualsF1-II1 andF1-II2,
the pool of glycoconjugates was located to the Golgi, and
immunofluorescence signal quantification in the Golgi
showed a clear reduction for all individuals, in agreement
with less efficient Golgi glycosylation (Figures 3A and 3B).
Additionally, we observed a dispersed pattern of the glyco-
conjugates, suggestive of dilatation of the Golgi (Figure 3B).
To investigate whether we could rescue the phenotype
of individual F1-II4, we transfected skin fibroblasts
with a construct containing either a mock construct or
CCDC115 wild-type sequence. As seen in Figures 3C and
3D, fibroblasts transfected with a mock construct have a
non-detectable fluorescence intensity in the Golgi, in
contrast to fibroblasts transfected with a construct contain-
ing wild-type CCDC115.
In addition to metabolic labeling, we stained healthy
control fibroblasts and fibroblasts from affected individualan Journal of Human Genetics 98, 310–321, February 4, 2016 317
Figure 4. CCDC115-V5 Is Located in the
ER-to-Golgi Region
HeLa cells were transiently transfected with
a V5-tagged CCDC115 construct and then
fixed and stained with immunofluores-
cently labeled antibodies against V5 (green
in merge) and different organelle markers
(magenta in merge). Shown are representa-
tivecells stainedforCCDC115-V5,organelle
markers, and amergewithDAPI stain (blue),
including a 3-fold magnification. Co-locali-
zation is indicated by white color in the
merged channel. The graphs show the fluo-
rescence intensity profiles along the cross-
sections indicated.Scalebars represent5mm.F2-II1 with anti-calnexin antibody to visualize the ER
(Figure 3E). Individual F2-II1 fibroblasts showed a dilated
ER in 60% of counted cells, in comparison to 20% in
healthy control fibroblasts.Localization
To define the subcellular location of CCDC115, we con-
structed a pcDNA3.1-CCDC115-V5 plasmid for transient
expression of C-terminally V5-tagged CCDC115 in HeLa
cells. Confocal imaging revealed clear localization to the
ER-Golgi intermediate compartment (ERGIC) and coat
protein complex I (COPI) vesicles (Figure 4). Also, in
immortalized human hepatocytes (HepaRG), CCDC115
located to the ERGIC and COPI vesicles (data not shown).
Partial co-localization was seen in both cell types with CO-
PII and Golgi markers. No co-localization was seen with
the ER marker PDI (Figure 4). We conclude that
CCDC115 predominantly localizes to the ER-to-Golgi re-
gion but not to the ER, in contrast to yeast Vma22p.318 The American Journal of Human Genetics 98, 310–321, February 4, 2016Discussion
We identified CCDC115 mutations in
eight individuals from five unrelated
families, and we provide evidence
that these mutations affect protein
N- and mucin-type O-glycosylation
via their effect on Golgi homeostasis.
Also, we showed that CCDC115 is
localized to the ER-to-Golgi region.
However, the question remains—
what is the function of CCDC115
and how does its deficiency result in
abnormal protein glycosylation and
clinical symptoms?
Previous studies in mice suggest
localization of CCDC115 to the lyso-
somal-endosomal system and upregu-
lation of Ccdc115 in mouse cortical
neurons after fibroblast growth factor
2 (FGF2) stimulation.29 Overexpres-
sion of Ccdc115 in mouse embryonicfibroblasts has been shown to have a positive effect on
cell proliferation.30 Our data suggest a physiological role
for CCDC115 in Golgi homeostasis, and loss-of-function
mutations lead to the inability of the Golgi to perform its
core functions: post-translational modification and pro-
tein secretion and sorting. A disturbance in Golgi
homeostasis is indicated by the combined defect of N-
and O-glycosylation. Detailed structural studies on N-gly-
cans revealed an accumulation of incomplete glycans lack-
ing both sialic acid and galactose. These data indicate a
general disturbance in Golgi homeostasis with an effect
on multiple glycosylation pathways, for example, via
incorrect targeting and/or recycling of glycosyltransferases
and nucleotide-sugar transporters. Previously, deficient ve-
sicular transport has been proposed as explanation for
abnormal Golgi glycosylation in COG and ATP6V0A2 de-
fects.5,10 Localization of CCDC115 to, among others,
COPI vesicles that are involved in ER-to-Golgi transport
and sorting of cargo proteins, could indicate a similar
mechanism.
Based on comparative genomics, it is likely that
CCDC115 and the yeast protein Vma22p are orthologs
and have, at least partially, overlapping functions.
Vma22p is involved in assembly of the V-ATPase proton
pump by stabilizing the V0 domain during early assembly
in the ER. Vma22 knockout yeast showed diminished
V-ATPase activity and destabilization of the V0 domain.31
Possibly, mutations in CCDC115 could exert part of the ef-
fect via alteration of V-ATPase assembly or function.
Vma22p exerts its function as a V-ATPase assembly factor
by interacting with Vph2p (also called Vma12p [GenBank:
NP_012803]) and Vma21p (GenBank: NP_011619.3).27 In
another study in this issue, we have identified TMEM199
(also known as C17orf32 [GenBank: NP_689677.1]) as the
human homolog of Vph2, and recently VMA21 (GenBank:
NP_001017980.1) has been described as the human homo-
log of Vma21p.32,33
Individuals with TMEM199 deficiency showed partial
clinical and biochemical overlap with CCDC115-defi-
cient individuals, although symptoms seem to be milder.
TMEM199-deficient individuals presented in adolescence
with a phenotype of elevated ATs and ALP, hypercholester-
olemia, hepatic steatosis, and low ceruloplasmin. Profound
hepatosplenomegaly and PMD, as seen in CCDC115
deficiency,wereabsent.Compared toknownV-ATPase-asso-
ciated disorders, CCDC115 deficiency (and TMEM199 defi-
ciency) is thefirst thatpredominantly affects the liver.34Mu-
tations in VMA21 cause X-linked myopathy with excessive
autophagy (XMEA [MIM: 310440]).XMEA is a disorder asso-
ciated with progressive muscle weakness.35,36 Mutations in
V-ATPase subunits TCIRG1 (also called ATP6V0A3) and
ATP6V0A4 cause tissue-specific symptoms (osteopetrosis
[MIM: 259700] and distal renal tubular acidosis [MIM:
602722]).37,38 A hallmark clinical feature of ATP6V0A2-
affected individuals is cutis laxa.39 Biochemically,
ATP6V0A2 deficiency is highly similar to CCDC115 (and
TMEM199) deficiency with defective N- and O-glycosyla-
tion.10,40 Interestingly, themost severely affected individual
(F5-II1)wasdiagnosedwith redundant skinandpoormuscle
volume, symptoms characteristic of ATP6V0A2 andVMA21
deficiency, respectively. This hints at a phenotypical contin-
uum among several V-ATPase-associated disorders.
The storage-disease-like phenotype of CCDC115 defi-
ciency resembles that of lysosomal disease, such as
Niemann-Pick disease type C (NPC, caused by mutations
in NPC1 and NPC2 [MIM: 257220]). NPC is characterized
by hepatosplenomegaly and neurologic manifestations.41
Lysosomal accumulation of cholesterol and sphingomye-
lin due to impaired cholesterol trafficking is the hallmark
of NPC; hence, NPC can be regarded as a cholesterol traf-
ficking disease.42 NPC1 and NPC2 work in conjunction
with each other and are involved in the transport of
cholesterol from late endosomes and lysosomes to the
plasma membrane and ER. Interestingly, binding of
cholesterol to NPC2 is improved in an acidic environment,
and this could be a possible link between CCDC115 defi-
ciency and NPC, given that the V-ATPase is the main acid-The Americifier of lysosomal pH.43 Alternatively, altered trafficking of
lysosomal proteins could explain the clinical resemblance.
All individuals had elevated serum ALP on biochemical
analysis. This was determined to be bone derived for the
investigated individuals. Discrepantly high bone-derived
ALP can be observed in individuals with defects of GPI
anchor biosynthesis.44,45 However, this is not supported
for CCDC115 deficiency. Trafficking of GPI-anchored pro-
teins, which might include ALP, is suggested to occur
through a COPII-dependent process from ER exit sites.46
InVma22pmutant yeast, traffickingofALP to the yeast vac-
uole is not majorly altered.31 However, yeast ALP is mem-
brane bound and not a GPI-anchored protein. Treatment
of yeast with bafilomycin A1, a potent V-ATPase inhibitor
known to block vacuole acidification, did not show any
effect on trafficking and maturation of membrane-bound
yeast ALP.47 This suggests that transport of vacuolar mem-
brane proteins, including ALP, in yeast is independent
from acidification. A study in mouse pituitary corticotrope
tumor cells showed decreased trafficking of cargo proteins,
independent of pH, after incubation with Concamycin A
(ConA), another V-ATPase inhibitor. Although knockdown
of the V-ATPase showed an overlapping phenotype with
ConA treatment, thiswasnot investigated for protein secre-
tion. Additionally, processing of the investigated protein,
PC1, begins in the trans-Golgi network and could therefore
not be representative for Golgi trafficking.48 Based on the
localization of CCDC115 in the ER-to-Golgi region, it could
be speculated that CCDC115 has a role in protein cargo
sorting or trafficking of alkaline phosphatase in addition
to a possible role in V-ATPase assembly.
In conclusion, we describe eight individuals with a type
2 CDG from five unrelated families affected by mutations
in CCDC115. The phenotype consists of elevated amino-
transferases and alkaline phosphatase and hepatospleno-
megaly in combination with psychomotor disability,
hypercholesterolemia, and hypotonia. Based on homology
detection, glycosylation studies, and cellular co-localiza-
tion, we propose a role for CCDC115 in Golgi homeostasis.Accession Numbers
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